Frequent truncating mutations of STAG2 in bladder cancer. - Wikidata - awgldk - TriplyDB

Frequent truncating mutations of STAG2 in bladder cancer.

Frequent truncating mutations of STAG2 in bladder cancer.

http://www.wikidata.org/entity/Q37419131

about

Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes SMC complexes link gene expression and genome architecture Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer Cohesin mutations in myeloid malignancies: underlying mechanisms Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function.Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.Association between Polymorphisms in MicroRNAs and Risk of Urological Cancer: A Meta-Analysis Based on 17,019 Subjects.The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.Genetic alterations of the cohesin complex genes in myeloid malignancies.Cohesin gene mutations in tumorigenesis: from discovery to clinical significance Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.Enhancer alterations in cancer: a source for a cell identity crisis.Structure and function of cohesin's Scc3/SA regulatory subunit Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.Molecular biology of bladder cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy The three-dimensional cancer genome.Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma.New treatments for bladder cancer: when will we make progress?Cohesin in cancer: chromosome segregation and beyond.Functional interplay between cohesin and Smc5/6 complexes.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.The role of genomics in the management of advanced bladder cancer.Chromosome Dynamics during Mitosis.Targeting Signaling Transduction Pathways in Bladder Cancer.Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.BAF180 promotes cohesion and prevents genome instability and aneuploidy.The role of mutations in the cohesin complex in acute myeloid leukemia.

P2860

Q26801785-E7A9FFB2-8EE9-47C4-9C53-D17BBC5017DC Q26826804-CC27D876-E634-474F-B2E8-E7D66A260AF6 Q27008499-63126053-25E6-4D6B-9591-B1D2131E1FB3 Q27022740-CA43FAB0-A702-4010-AEEA-C685DA5F6D15 Q27853334-DD1CEBE2-9A9C-45A9-A56B-6C7E52535920 Q30279180-DF6B948D-3C99-4D41-AB69-8CFECA76791E Q30667509-7CA53836-9ED1-4AA3-A89F-C1BC645AF6EA Q33568623-E58C2AA1-6415-4F27-B579-B4C673BCA806 Q33707179-54291014-425D-465D-A56E-E4167B7C3E46 Q33881163-5A117BC4-5A32-44A6-8C14-9A0BF2F3B465 Q34034221-71B2D788-F5A3-4243-82B7-3680276076BA Q34081624-5ADEF105-D916-4E8A-9119-6B439CBE4EEC Q34170374-BB671746-2486-416A-A1CA-3D9BF64CFB51 Q34179964-9D984045-0496-415D-8B9C-E78C7FA240DF Q34199816-EE36CBE8-EF2B-405E-87DF-EF8C62C56B7E Q34624854-E11E7B75-74F7-42AB-AE3E-7D811F198764 Q34664181-D91B034B-EFE4-4433-ACD7-FF440688324A Q34667055-A8D96684-735C-45DE-ACDB-1F6D7368C379 Q34717001-F94621A8-4F6D-4B14-A959-590009AF00A4 Q35034441-33843780-CA68-4EB6-8A1D-6085ED9CA8F0 Q35266400-A55F0E89-20EB-49CC-8CF1-1085C3E9E5F4 Q35638497-6FFD22EA-18E5-408A-AD21-88B040220F97 Q35922216-F7672EE5-BBB6-4960-B56A-C6DC023B6369 Q36054919-4D3FBBE6-0B6D-4E3B-91F1-BC2F53FCB874 Q36180677-DA9D9FDD-7F37-4D61-8EE7-D7D3CA5A0953 Q36352394-D3D542E3-D2C8-424C-AF7F-2895E5C907EF Q36768782-A37AC368-2818-4ADF-8191-4802C74211E5 Q36936249-79FE405C-0BDB-407A-B6B0-50A774FB6B3E Q37239090-BB1E8F6A-6988-4A64-B2BE-551802FDCA25 Q37676840-44918D42-2B8B-4C23-B271-A081AEC7EA2A Q38177753-60E252B6-5A53-459D-B6C7-3AF1BCD4A2A4 Q38213986-0510A375-E885-4524-8CD9-C20289CAFF87 Q38224980-7139BA0B-C66D-4EAA-876C-DC873E72ADF8 Q38297729-F4810D2D-9AC1-42D9-9DCD-C0AE22154705 Q38342992-E2499E18-7A38-47B0-8AD3-A3589E866A40 Q38365781-5D3D2CB0-C6B4-4A34-A496-90CCA1CBE479 Q38608540-9ED0CD17-8CA3-4EDB-A7DA-03FE4702854D Q38692457-93B03AFB-F1B2-49D0-83BE-2F7A01273BC6 Q38786462-45AE667D-9D1F-4A33-B8A3-9A842D67D9EC Q38802248-11D1837E-141E-4556-B077-E52ED1876B10

P2860

Frequent truncating mutations of STAG2 in bladder cancer.

http://www.wikidata.org/entity/Q37419131

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Frequent truncating mutations of STAG2 in bladder cancer.

@en

Frequent truncating mutations of STAG2 in bladder cancer.

@nl

type

label

Frequent truncating mutations of STAG2 in bladder cancer.

@en

Frequent truncating mutations of STAG2 in bladder cancer.

@nl

prefLabel

Frequent truncating mutations of STAG2 in bladder cancer.

@en

Frequent truncating mutations of STAG2 in bladder cancer.

@nl

P1433

Q37419131-D20DD937-D6F2-490D-B18E-41E8C5B6DAE1

P1476

Q37419131-B87D7288-A4FD-4ABF-BE83-BB23B2F3277D

P2093

Q37419131-0B0A2CF2-8B12-4A6B-8074-A5D2F2A2837E

Q37419131-0F30255A-ACC6-433C-A07D-35651E0252B1

Q37419131-233C7FF3-6F04-44B1-A590-4AD119E01A41

Q37419131-2C31CCBC-DC3E-4315-973D-F4F789FC1700

Q37419131-356C7861-BEB3-4361-AA3A-AB23ADF948A9

Q37419131-37461B6E-5609-4369-823B-4FDB46374935

Q37419131-3875ADCC-BD26-4AAF-B986-E48F8AD05CB3

Q37419131-3A92A75A-C614-4235-82CF-71D567DCACB9

Q37419131-431DF735-B720-4E7B-964E-50AC404F514D

Q37419131-4B6E969D-A3B6-48C0-A9D6-A00F0E22ED35

P2860

Q37419131-08971111-9CD0-4C76-8E98-EFA43EB36A9C

Q37419131-0E825340-A331-4CD0-9E68-B5830D5E2EF8

Q37419131-0EE5488B-EA2C-4A98-8747-2E4F2533E445

Q37419131-55052D8B-E088-4037-B2EC-0C2A14A76044

Q37419131-78276307-A9CA-443C-AB12-DFB701EA2677

Q37419131-7C1923CD-E299-4A26-A184-D5FF9C728107

Q37419131-A7BD2538-EAD8-4844-837A-E08E9DF58836

Q37419131-C10834D6-BF15-4BFF-8F1D-16D4F3C49081

Q37419131-C85CB98D-CE67-42D4-BB85-7499E0D6FE5E

Q37419131-F4741337-1441-4AD0-BAF8-1340B959B100

P2888

Q37419131-A34D04D5-E6CD-46CE-889F-F8579CCA7020

P304

Q37419131-FCE28FA8-5F00-4981-94FC-02CA61F0B5E0

P31

Q37419131-EA7A7D17-585F-4754-817E-5EAF504EE2A5

P356

Q37419131-195BEEAC-360F-433B-BEC8-96102A838655

P407

Q37419131-DB6BD38B-8C89-455D-B424-BB877F544DD2

P433

Q37419131-2973F7D0-E9B7-4C49-A0A9-FA56089B6B19

P478

Q37419131-3FE1D436-DAA9-46F5-8422-9D46D9A60799

P50

Q37419131-55883879-C4E6-453E-A28D-7C88314A6FDC

Q37419131-CF0AADA0-23F7-4AE5-93AB-0B645B2CC92B

P577

Q37419131-5CD403EC-04C2-4C68-861F-0DB349D62F2D

P5875

Q37419131-41A16F03-10E9-42DE-A929-49EE5E3E0064

P698

Q37419131-00C4680E-EB95-456C-AD63-CCDE8C6ACCE9

P932

Q37419131-2BDE25F5-FE79-4EB9-9A3C-2A247ECD5875

P356

P1433

Nature Genetics

P1476

Frequent truncating mutations of STAG2 in bladder cancer.

@en

P2093

Abdel G Elkahloun

http://www.w3.org/2001/XMLSchema#string

Arlene Siefker-Radtke

http://www.w3.org/2001/XMLSchema#string

Björn Volkmer

http://www.w3.org/2001/XMLSchema#string

Bogdan Czerniak

http://www.w3.org/2001/XMLSchema#string

Brian D Robinson

http://www.w3.org/2001/XMLSchema#string

C David James

http://www.w3.org/2001/XMLSchema#string

Dan Theodorescu

http://www.w3.org/2001/XMLSchema#string

David A Solomon

http://www.w3.org/2001/XMLSchema#string

Dazhong Zhuang

http://www.w3.org/2001/XMLSchema#string

George Netto

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analyses of ovarian carcinoma

Cohesins: chromosomal proteins that prevent premature separation of sister chromatids

The origin and evolution of mutations in acute myeloid leukemia

Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors

A simple method for generating multitissue blocks without special equipment.

Clonal architecture of secondary acute myeloid leukemia.

Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres.

Mutational inactivation of STAG2 causes aneuploidy in human cancer

Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.

Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability.

P2888

P304

1428-1430

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NG.2800

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Pancras C.W. Hogendoorn

P577

2013-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257754494

http://www.w3.org/2001/XMLSchema#string

P698

24121789

http://www.w3.org/2001/XMLSchema#string

P932

3875130

http://www.w3.org/2001/XMLSchema#string